Burosumab-Twza Injection (Crysvita®)

Covered only for the FDA‑approved non‑oncology indication X‑linked hypophosphatemia (XLH); non‑XLH/non‑FDA uses are excluded. Initial approval requires prescription by or consultation with an endocrinologist/nephrologist, baseline low serum phosphorus prior to any XLH treatment plus either low TmP/GFR or a PHEX mutation, adults must have ≥1 XLH symptom and a trial of (or contraindication to) oral phosphate + calcitriol, approvals are for 12 months with documented benefit required for reauthorization, and dosing is limited to a maximum 90 mg subcutaneously (adults no more frequently than every 4 weeks; pediatric dosing no more frequently than every 2 weeks).

"Treatment of X-linked hypophosphatemia (XLH) (FDA‑approved non-oncology indication)."

Sign up to see full coverage criteria, indications, and limitations.